According to filings with the U.S. Securities and Exchange Commission, Turnstone Biologics is raising $80,000,000.00 in new funding. About Turnstone Biologics: Turnstone Biologics is a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to TIL therapy. Our innovative TIL therapy is based upon the identification, selection, and expansion of the most potent tumor-reactive T cells, known as Selected TILs, and is designed to overcome the limitations of first-generation bulk TILs that have demonstrated objective responses only in limited tumor types. Our most advanced program, TIDAL-01, is currently being evaluated in two Phase 1 studies in patients with melanoma, breast cancer, and colorectal cancer. We are also actively advancing a pipeline of preclinical programs, including TIDAL-02, our next Selected TIL program, and our TIDAL-01 and viral immunotherapy combination program.

To learn more about Turnstone Biologics, visit http://turnstonebio.com/

Contact:
David Stojdl, Co-Founder
347-897-5988
https://www.linkedin.com/in/david-stojdl-5a7466206/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.